Peter Hawryluk
CEO, President & Director

Welcome to everyone in the room and on webcast, and thank you for joining us for Obesity Day. Today, we are excited and honored to present our novel and transformative approach to treating this global chronic disease. We've experienced increasing interest in learning about our obesity portfolio. We thought this was a timely opportunity to highlight our remarkable progress, which we are making toward our 2026 milestones.

Standing tallest is 12-week MAD data in Q4 for MBX 4291, our GLP-1/GIP coagonist prodrug. We said that it would be important to show true once-monthly dosing and improve tolerability as a monthly drug. We also said we should expect to see competitive weight loss given these are the gold standard mechanisms.

Sam Azoulay, CMO, will present preliminary data from our ongoing blinded Phase I study, which demonstrate this target product profile. We're very encouraged by what we're seeing with MBX 4291, which reads through to our entire expanding obesity portfolio, all built on our proprietary PEP technology.

We're joined today by two leaders in